The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

InflaRx Presents Phase 3 Vilobelimab Data at AAD 2026 Annual Meeting

Key Facts

1InflaRx announced the presentation of Phase 3 study data for vilobelimab in pyoderma gangrenosum (PG).

2The data was featured in a late-breaker oral presentation at the 2026 American Academy of Dermatology (AAD) Annual Meeting.

3InflaRx (Nasdaq: IFRX) focuses on anti-inflammatory therapeutics by targeting the complement system.

Create Free Account

Version History

1 additional source confirmed this story

InflaRx N.V. (Nasdaq: IFRX) announced the presentation of its Phase 3 clinical trial data for vilobelimab at the 2026 American Academy of Dermatology (AAD) Annual Meeting. The data, focusing on the treatment of pyoderma gangrenosum (PG), was featured in a high-profile late-breaker oral presentation in Denver. Vilobelimab is a first-in-class monoclonal antibody designed to target the complement system to manage inflammatory conditions. This presentation marks a significant milestone for the company as it shares late-stage clinical activity and safety results with the global medical community. The successful showcase of Phase 3 results often serves as a critical step toward regulatory filings and potential commercialization. Investors are closely monitoring these developments as they validate InflaRx's therapeutic pipeline and research capabilities.